ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile scleroderma"

  • Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium

    Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

    Suzanne Li1, Mara Becker 2, Sandy Hong 3, Polly Ferguson 4, Themba Nyrienda 5, Tracy Andrews 6, Katie Stewart 7, C. Egla Rabinovich 8, Robert Fuhlbrigge 9, Thomas Mason 10, Elena Pope 11, Maria Ibarra 12, Fatma Dedeoglu 13, Gloria Higgins 14, Ronald Laxer 15, Marilynn Punaro 16 and Kathryn Torok 17 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 3University of Iowa Stead Family Children's Hospital, Iowa City, 4University of Iowa Carver College of Medicine, Iowa City, 5Hackensack Univesity Medical Center, Hackensack, 6Rutgers University, Newark, 7UT Southwestern, Dallas, 8Duke University Hospital, Durham, 9University of Colorado, Aurora, 10Rochester, 11Hospital For Sick Kids, Toronto, Canada, 12Children's Mercy Kansas City, Kansas City, 13Boston Children's Hospital, Boston, 14Nationwide Childrens Hospital/ The Ohio State University, Columbus, 15The Hospital for Sick Children and University of Toronto, Toronto, Canada, 16Dallas, Texas, 17Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
  • Abstract Number: 023 • 2020 Pediatric Rheumatology Symposium

    Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score

    Suzanne Li1, Aashka Patel 2, Elena Pope 3, Thomas Mason 4, Vidya Sivaraman 5, Fatma Dedeoglu 6, Kathryn Torok 7, Katie Stewart 8, Gloria Higgins 9, C. Egla Rabinovich 10, Robert Fuhlbrigge 11, Maria Ibarra 12, Sandy Hong 13, Polly Ferguson 14, Mara Becker 15, Brian Feldman 16 and Ronald Laxer 17 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Hackensack University Medical Center, Hackensack, 3Hospital For Sick Kids, Toronto, Canada, 4Rochester, 5Division of Rheumatology, Nationwide Children's Hospital, Bexley, 6Boston Children's Hospital, Boston, 7Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 8UT Southwestern, Dallas, 9Nationwide Childrens Hospital/ The Ohio State University, Columbus, 10Duke University Hospital, Durham, 11University of Colorado, Aurora, 12Children's Mercy Kansas City, Kansas City, 13University of Iowa Stead Family Children's Hospital, Iowa City, 14University of Iowa Carver College of Medicine, Iowa City, 15Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 16The Hospital for Sick Children, Toronto, Canada, 17The Hospital for Sick Children and University of Toronto, Toronto, Canada

    Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in…
  • Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium

    Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

    Suzanne Li1, Sarah Ishaq 2, Mary Buckley 3, Kathryn Torok 4, Barbara Edelheit 5, Kaleo Ede 6 and C. Egla Rabinovich 7, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Montclair State University, montclair, 3Duke University, Durham, 4Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 5CT Children's Medical Center, Hartford, 6Phoenix Children's Hospital, Phoenix, 7Duke University Hospital, Durham

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
  • Abstract Number: 025 • 2020 Pediatric Rheumatology Symposium

    HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma

    Christina Schutt1, Emily Mirizio 2, Kaila Schollaert-Fitch 2 and Kathryn Torok 2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, 2Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue that is characterized by an earlier inflammatory infiltrate, followed by…
  • Abstract Number: 771 • 2019 ACR/ARP Annual Meeting

    Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma

    Natalia Vasquez-Canizares1, Beamon Agarwal 2, Tamar Rubinstein 3, Dawn Wahezi 4 and Morayma Reyes Gil 5, 1Children's Hospital at Montefiore, Bronx, NY, 2GenomeRxUS LLC, Providence, PA, 3Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, 4Children’s Hospital at Montefiore, New York, 5Montefiore Medical Center/Albert Einstein College of Medicine, Bronx

    Background/Purpose: Von Willebrand Factor (VWF) is a glycoprotein synthesized in endothelial cells and megakaryocytes that has an essential role in primary hemostasis. There is increasing…
  • Abstract Number: 776 • 2019 ACR/ARP Annual Meeting

    Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma

    Christina Schutt1, Emily Mirizio 2, Claudia Salgado 3, Miguel Reyes-Mugica 3, Kaila L. Schollaert 2 and Kathryn Torok 3, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3UPMC Children's Hospital of Pittsburgh, Pittsburgh

    Background/Purpose: Localized scleroderma (LS) is a progressive autoimmune disease of the skin and underlying tissue that is characterized by an initial inflammatory infiltration which is…
  • Abstract Number: 791 • 2019 ACR/ARP Annual Meeting

    Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

    May Choi1, Emily Mirizio 2, Fernanda Quinteros 3, Katherine Buhler 4, Marvin Fritzler 1 and Kathryn Torok 5, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Pittsburgh, Pittsburgh, 3University of Calgary, Calgary, 4University of Calgary, Calgary, Canada, 5UPMC Children's Hospital of Pittsburgh, Pittsburgh

    Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We…
  • Abstract Number: 792 • 2019 ACR/ARP Annual Meeting

    Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis

    Giovanni Civieri 1, Biagio Castaldi 1, Giorgia Martini 1, Alessandra Meneghel 1, Ornella Milanesi 1 and Francesco Zulian2, 1Dept. of Woman's and Child's Health, university of Padua, Italy, Padua, Italy, 2Department of Woman and Child Health, University of Padua, Italy, Padova, Italy

    Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare connective tissue disease in which cardiac involvement is burdened by high morbidity and mortality. The traditional cardiac…
  • Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting

    Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis

    Katharine Moore1,2, Marvin J. Fritzler3, Marisa S. Klein-Gitelman4, Ann M Reed5, Tzielan Lee6 and Anne Stevens7,8, 1Pediatrics, University of Colorado, Aurora, CO, 2Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, 3Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 5Rheumatology, Duke University, Durham, NC, 6Pediatric Rheumatology, Stanford University, Palo Alto, CA, 7University of Washington, Department of Pediatrics, Seattle, WA, 8Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…
  • Abstract Number: 2390 • 2016 ACR/ARHP Annual Meeting

    Proposal of Assessment of  the Activity of Juvenile Localised Scleroderma. Results of the Consensus Meeting in Hamburg, Germany December 2015

    Ivan Foeldvari1, Eileen Baildam2, Michael Blakley3, Christina Boros4, Kim Fligelstone5, Antonia Kienast1, Dana Nemkova6, Clare Pain2, Amanda Saracino4, Gabriele Simonini7, Kathryn S. Torok8, Lisa Weibel9 and Nicola Helmus1, 1Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 2Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 3Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, 4Pediatric Rheumatology, London, United Kingdom, 5Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 6Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 7Pediatric Rheumatology, Anna Meyer Children's Hospital, Florence, Italy, 8Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 9Pediatric Dermatology, University Childrenxs Hospital, Zurich, Switzerland

    Background/Purpose:  Juvenile Localised Scleroderma (JLS) is an orphan disease which is complicated by difficulties in robust measurement of disease activity.   Several outcome measures to assess…
  • Abstract Number: 420 • 2015 ACR/ARHP Annual Meeting

    Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Eveline Y. Wu1, Suzanne C. Li2, Kathryn S. Torok3, Yamini Virkud4, Robert C. Fuhlbrigge5, C. Egla Rabinovich6 and CARRA Registry Investigators, 1Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Pediatrics, Hackensack University Medical Center, Hackensack, NJ, 3Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 4Pediatrics, Massachusetts General Hospital for Children, Boston, MA, 5Pediatric Rheumatology, Boston Children's Hospital, Boston, MA, 6Pediatric Rheumatology, Duke University Medical Center, Durham, NC

    Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease. We present baseline data on the juvenile LS (jLS) cohort from the Childhood…
  • Abstract Number: 424 • 2015 ACR/ARHP Annual Meeting

    Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of  Cardiac Involvement in Juvenile Systemic Sclerosis

    Francesco Zulian1, Marta Balzarin1 and Elena Reffo, Biagio Castaldi, Giorgia Martini, Alessandra Meneghel, Ornella Milanesi, 1Department of Pediatrics, University of Padua, Padua, Italy

    Background/Purpose: Cardiac involvement is one of the worst prognostic factors in JSSc. The diagnosis is usually based on clinical symptoms, EKG and conventional echocardiography, but…
  • Abstract Number: 2178 • 2013 ACR/ARHP Annual Meeting

    Juvenile Onset Systemic Sclerosis: Clinical and Serological Features, and Mortality In Comparison With Adult Onset Disease

    Juan G. Ovalles-Bonilla1, Francisco Javier López-Longo2, Indalecio Monteagudo1, Esperanza Naredo1, Carlos Gonzalez Fernandez1, María Montoro Alvarez1, Lina Martínez-Estupiñán1, Juan C. Nieto3, Julia Martínez-Barrio1, Michelle Hinojosa1, Natalia Bello1, Belen Serrano1, Carmen Mata1 and Luis Carreño1, 1Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, 3Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Currently data regarding long-term outcome of juvenile systemic sclerosis (jSSc) is scarce. To describe the differences between patients with jSSc versus adult onset evaluated at a single medical…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology